The Q3 top-line numbers came in better than expected – pricing pressure seems to be moderating. Although Sandoz is yet to see biosimilars take off, the chemical-based generics continue to pull it down. Alcon continued the strong performance that began in Q2, but the review has now been pushed to 2019. The pipeline has proven fairly productive in the last few months, with positive clinical trials and regulatory decisions.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Positive signals
Novartis AG (0QLR:LON) | 0 0 0.7% | Mkt Cap: 208,186m
- Published:
08 Jan 2018 -
Author:
Kamla Singh - Pages:
The Q3 top-line numbers came in better than expected – pricing pressure seems to be moderating. Although Sandoz is yet to see biosimilars take off, the chemical-based generics continue to pull it down. Alcon continued the strong performance that began in Q2, but the review has now been pushed to 2019. The pipeline has proven fairly productive in the last few months, with positive clinical trials and regulatory decisions.